Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026 Additional Data from Phase 2 ARCHER Trial Demonstrated Both Significant Vision ...

Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians ARCHER II, a Global Sham-Controlled ...

DUBLIN--(BUSINESS WIRE)--The "Spinal Muscular Atrophy (SMA) Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, Intrathecal), By Treatment (Gene Therapy, Drug), By ...

Please provide your email address to receive an email when new articles are posted on . Dec. 5 is World Geographic Atrophy Day, a new initiative that seeks to empower individuals with this advanced ...

Muscle atrophy is a primary characteristic of both sarcopenia and cachexia, significantly impacting physical function and quality of life. This figure illustrates the multifaceted causes of muscle ...